TAIPEI and SAN DIEGO, Sept. 13, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Silmitasertib (CX-4945) was granted a…